Catabasis Pharmaceuticals, Inc

CATB NASDAQ

PlanTradePlanMM

Bottom Wedge Price > SMA13 OBV> OBV34 WR > -80 Entry 2.2 Stop 1.5 Target 7 Risk management is much more important than a good entry point. The max Risk of each plan should be less than 1% of an account. I am not a PRO trader. I trade option to test my trading plan with small cost.

TechieTrades

$CATB should get a bounce here and run to $2.25s

LadyAmalthea12

$CATB Target 5.48 for 39.09% Or next add level is at anywhere around here. The more I add the higher my percentage profit when this runs again... Added a little here and will add more soon. — On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average. I start every position...

LadyAmalthea12

$CATB Target 5.52 for 38.69% Or next add level is at 2.43 I added twice here today... brought my average down a bit and brought target closer... — On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average. I start every position with 1% of my account and build from there...

TechieTrades

$CATB $4.00 next resistance if breaks, gap fill to $5.50s coming

LadyAmalthea12

$CATB Target 5.79 for 36.24% Or next add at 2.71 I am not your financial advisor. My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. GL

GhazKhan

I don't know what this curve means. Is that something real? I would like experts to comment and kindly explain this pattern, please.

PlanTradePlanMM

Measuring Gap Wedge Entry 3.5 no Stop Target 8.5 I am not a PRO trader. I trade option to test my trading plan with small cost. The max Risk of each plan is less than 1% of my account. If you like this idea, please use SIM/Demo account to try it.

AlenCiken

Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc. Acquisition Includes QLS-215, a Potential Best-in-Class Monoclonal Antibody Inhibitor of Plasma Kallikrein in Preclinical Development for the Treatment of Hereditary Angioedema Concurrent with the acquisition of Quellis, Catabasis entered into a definitive agreement for the sale of...

shkspr

NASDAQ:CATB Possible Scenario: LONG Evidence: Price Action This is my idea and could be wrong 100%.

Bullishcharts

Some very bullish action pre market Indicators bullish Major Gap above with little to no price resistance

KozakHlib

Pupm&Dump trading strategy idea. $CATB is rising without clear preconditions today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $2,05; stop-loss — $2,42; take-profit — $1,68; Do not view this idea as a recommendation for trading or...

SimpleFX63

TEST

swish30

Could see high volatility given that this is there main product.

Bullish_Swag

Higher Lows... Watch into PH

showerreport

Oversold and carwled enough .. ready to rumble